Managed Care - September 2008 - (Page 35)

In moderate to severe Alzheimer’s disease Recognize the value of treatment with NAMENDA Treat today with NAMENDA—delivers proven efficacy and may reduce total healthcare costs1-5 Patients with Alzheimer’s disease are complex and present unique challenges to managed care organizations Comorbid conditions, such as congestive heart failure and diabetes, are more common and more expensive to manage in patients with Alzheimer’s disease6 The proven efficacy of NAMENDA can help you meet these challenges NAMENDA treatment benefits in cognition and function could reduce the costs of comorbid conditions1-3,6 Behavioral issues are a major contributor to increased costs in Alzheimer’s disease7 NAMENDA improves behavior and delays the onset of behavioral symptoms in combination with an acetylcholinesterase inhibitor (AChEI)1,4 Patients with Alzheimer’s disease who received NAMENDA demonstrated reduced total healthcare costs5 The value of treatment with NAMENDA n n n n Unique mechanism of action—in a class of its own8-13 Efficacy in cognition and function, alone or in combination with an AChEI1-3 Efficacy in behavior in combination with an AChEI1,4 Excellent safety and tolerability may improve therapy persistence5,8,14 NAMENDA® (memantine HCI) is indicated for the treatment of moderate to severe Alzheimer’s disease. NAMENDA is contraindicated in patients with known hypersensitivity to memantine HCl or any excipients used in the formulation. The most common adverse events reported with NAMENDA vs placebo (≥5% and higher than placebo) were dizziness, confusion, headache, and constipation. In patients with severe renal impairment, the dosage should be reduced. References: 1. Tariot PN, Farlow MR, Grossberg GT, Graham SM, McDonald S, Gergel I, for the Memantine Study Group. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA. 2004;291:317-324. 2. Reisberg B, Doody R, Stöffler A, Schmitt F, Ferris S, Möbius HJ, for the Memantine Study Group. Memantine in moderate-to-severe Alzheimer's disease. N Engl J Med. 2003;348:1333-1341. 3. Reisberg B, Doody R, Stöffler A, Schmitt F, Ferris S, Möbius HJ. A 24-week open-label extension study of memantine in moderate to severe Alzheimer disease. Arch Neurol. 2006;63:49-54. 4. Cummings JL, Schneider E, Tariot PN, Graham SM, for the Memantine MEM-MD-02 Study Group. Behavioral effects of memantine in Alzheimer disease patients receiving donepezil treatment. Neurology. 2006;67:57-63. 5. Wimo A, Winblad B, Stöffler A, Wirth Y, Möbius HJ. Resource utilisation and cost analysis of memantine in patients with moderate to severe Alzheimer's disease. Pharmacoeconomics. 2003;21:327-340. 6. Hill JW, Futterman R, Duttagupta S, Mastey V, Lloyd JR, Fillit H. Alzheimer's disease and related dementias increase costs of comorbidities in managed Medicare. Neurology. 2002;58:62-70. 7. Murman DL, Chen Q, Powell MC, Kuo BS, Bradley CJ, Colenda CC. The incremental direct costs associated with behavioral symptoms in AD. Neurology. 2002;59:1721-1729. 8. NAMENDA® (memantine HCl) Prescribing Information. Forest Pharmaceuticals, Inc., St Louis, Mo. 9. Aricept® (donepezil hydrochloride tablets) Prescribing Information. Eisai Inc., Woodcliff Lake, NJ. 10. Razadyne® (galantamine HBr) Prescribing Information. Ortho-McNeil Neurologics, Inc., Titusville, NJ. 11. Exelon® (rivastigmine tartrate) Prescribing Information. Novartis Pharmaceuticals Corporation, East Hanover, NJ. 12. Cognex® (tacrine hydrochloride capsules) Prescribing Information. Sciele Pharma, Inc., Atlanta, Ga. 13. United States Pharmacopeia. Medicare Prescription Drug Benefit Model Guidelines Version 3.0: Drug Categories and Classes in Part D. Rockville, Md: United States Pharmacopeial Convention, Inc.; February 5, 2007. 14. Data on file. Forest Laboratories, Inc. For more details, please visit www.namenda.com. Please see brief summary of Prescribing Information on the adjacent page. © 2008 Forest Laboratories, Inc. 62-1012188M 06/08 http://www.namenda.com http://www.namenda.com

Table of Contents Feed for the Digital Edition of Managed Care - September 2008

Managed Care - September 2008 Editor’s Memo Contents Legislation & Regulation News and Commentary Medication Management Compensation Monitor Archimedes Lends Hippocrates a Hand Some Other Predictive Modeling Programs Messing With Medicare Advantage The Trouble With MAC MedPAC’s Suggestions Sound Familiar The Leader in Patient Satisfaction Formulary Files Plan Watch Tomorrow’s Medicine Ad Index Outlook

Managed Care - September 2008

For optimal viewing of this digital publication, please enable JavaScript and then refresh the page. If you would like to try to load the digital publication without using Flash Player detection, please click here.